Investor Presentaiton
134
Investor presentation Full year 2022
North America Operations at a glance.
Diabetes trend in population
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
NAO
Million
DKK
Full year 2022
billion
Sales
(MDKK)
Growth²
70
10%
800
80%
Total GLP-13
57,175
36%
60
11%
Long-acting insulin
5,338
-32%
50
600
60%
Premix insulin5
539
-31%
41.0%1
Fast-acting insulin6
6,637
-13%
40
GLP-1
Human insulin
1,678
-7%
400
40%
30
63
Total insulin
14,192
-21%
57
51
Insulin
2.1%1
Other Diabetes care?
797
-25%
20
20
200
20%
Diabetes care
72,164
18%
10
16.0%¹
OAD
Obesity care
10,978
85%
0
2021
0
0%
Diabetes & Obesity
Nov
2030
2045
2017
Nov
2022
83,142
24%
care
Population with diabetes
Diabetes growth rate
Rare disease⁹
7,965
-5%
-GLP-1 MS
-Insulin MS
OAD MS
Total
91,107
21%
International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 10th Edition 2021
1 CAGR calculated for 5-year period
Competitor insulin value market shares, as of Nov 2022: Novo
Nordisk 43%, Eli Lilly 30% and Sanofi 25%; Competitor GLP-1
value market shares, as of Nov 2022: Novo Nordisk 54%, Eli Lilly
45% and AstraZeneca 2%
OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT,
Nov 2022 value figures
2 At constant exchange rates; 3 Comprises Victoza®, Ozempic®, and RybelsusⓇ;
4 Comprises Tresiba®, XultophyⓇ and Levemir®; 5 Comprises NovoMixⓇ;
6 Comprises FiaspⓇ and NovoRapidⓇ; 7 Comprises Novo NormⓇ and needles; 8
Comprises SaxendaⓇ and WegovyⓇ9 Comprises primarily NovoSevenⓇ,
Novo Eight® Esperoct®, NovoThirteen®, Refixia®, Norditropin®, VagifemⓇ and
Activelle®View entire presentation